Leavitt Partners December 1, 2022
Kristin Allen

Leavitt Partners examined publicly available resources to determine the 340B Drug Pricing Program’s (340B) impact on drug prices charged by both covered entities and pharmaceutical manufacturers. To answer these questions, Leavitt Partners undertook a comprehensive literature review of publicly available governmental reports, peer-reviewed journal articles, white papers, news articles, and other publicly available sources to identify the degree to which, and to what...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Govt Agencies, Health System / Hospital, Healthcare System, HHS, Insurance, Medicare, Pharma, Pharma / Biotech, Pricing / Spending, Provider, Survey / Study, Trends
FTC pauses PBM litigation in win for Caremark, Express Scripts, Optum Rx
Pharma Dodges The Tariff Bullet — But For How Long?
Noom, LillyDirect pharmacy provider partner to increase access to Zepbound
Robots can aid hospital pharmacies in safer and more sustainable cancer drug preparation
PBM Private Labeling Boosts Biosimilars, Raises Concerns

Share This Article